{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-056966","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2026-08-14T13:36:58+00:00","discovered_at":"2026-08-14T13:38:00.378331+00:00","generated_at":"2026-08-14T13:38:08.120189+00:00","sec_items":["1.01","3.02","3.03","5.01","5.02","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Skye Bioscience to acquire Redx Pharma; Redx holders to own ~46% of combined company","bullets":["Skye to acquire Redx Pharma via UK scheme of arrangement; Redx valued at $125M, Skye at $14.5M.","Post-close ownership: Redx shareholders ~46.17%, Skye ~5.38%, new investors ~48.45% (assuming $67.9M concurrent financing).","Concurrent financing of $67.9M (up to $72.9M) plus $5M side letter and $22M equity line; warrant valued at $5M.","Redx management to lead combined company: Lisa Anson CEO, Peter Collum CFO; current Skye executives and board to resign.","Shareholders to receive CVRs: Skye legacy CVR (90% of net proceeds from certain assets) and Redx CVR (100% of Redx asset proceeds)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-056966","json":"https://secwatch.observer/filing/0001628280-26-056966.json","markdown":"https://secwatch.observer/filing/0001628280-26-056966.md","text":"https://secwatch.observer/filing/0001628280-26-056966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/0001628280-26-056966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/skye-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T13:38:08.120189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ea3ee2342","claim":"Tu Diep departed as other_named_officer at Skye Bioscience, Inc..","evidence_excerpt":"Tu Diep has entered into a previously disclosed executive employment agreement (the “ Diep Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Diep (the “ Diep Separation Agreement ”) pursuant to which Mr. Diep's last day of employment with the Company will be January 31, 2027","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/0001628280-26-056966-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"separate"}],"fact_type":"executive_change"},{"claim_id":"90c3dfd073","claim":"Punit Dhillon departed as other_named_officer at Skye Bioscience, Inc..","evidence_excerpt":"Punit Dhillon has entered into a previously disclosed executive employment agreement (the “ Dhillon Employment Agreement ”) with the Company. In connection with the Transaction, on the date hereof, the Company entered into a separation agreement with Mr. Dhillon (the “ Dhillon Separation Agreement ”) pursuant to which Mr. Dhillon's last day of employment with the Company will be August 31, 2027","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/0001628280-26-056966-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"separate"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}